Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:CLLS NASDAQ:FTLF NASDAQ:SNDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.98+1.7%$3.15$2.56▼$7.73$579.53M0.184.36 million shs2.59 million shsCLLSCellectis$3.63-1.1%$3.70$1.33▼$5.48$364.23M2.9440,189 shs29,099 shsFTLFFitLife Brands$9.86-0.7%$10.66$8.67▼$20.98$92.60M-0.0124,843 shs33,378 shsSNDLSNDL$1.45+0.7%$1.42$1.15▼$2.89$373.23M0.881.81 million shs596,187 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+1.03%+6.93%+2.99%-35.75%-48.69%CLLSCellectis+4.86%+1.10%-5.66%-12.20%+149.66%FTLFFitLife Brands-1.39%-0.70%+5.86%-34.46%-31.89%SNDLSNDL-0.69%+4.35%-4.64%-7.10%+11.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.98+1.7%$3.15$2.56▼$7.73$579.53M0.184.36 million shs2.59 million shsCLLSCellectis$3.63-1.1%$3.70$1.33▼$5.48$364.23M2.9440,189 shs29,099 shsFTLFFitLife Brands$9.86-0.7%$10.66$8.67▼$20.98$92.60M-0.0124,843 shs33,378 shsSNDLSNDL$1.45+0.7%$1.42$1.15▼$2.89$373.23M0.881.81 million shs596,187 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+1.03%+6.93%+2.99%-35.75%-48.69%CLLSCellectis+4.86%+1.10%-5.66%-12.20%+149.66%FTLFFitLife Brands-1.39%-0.70%+5.86%-34.46%-31.89%SNDLSNDL-0.69%+4.35%-4.64%-7.10%+11.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.50Moderate Buy$16.67459.28% UpsideCLLSCellectis 2.83Moderate Buy$6.7585.95% UpsideFTLFFitLife Brands 2.25Hold$21.50118.05% UpsideSNDLSNDL 1.67Reduce$5.00244.83% UpsideCurrent Analyst Ratings BreakdownLatest FTLF, SNDL, CLLS, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026ALTAltimmune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00 ➝ $20.005/14/2026ALTAltimmune Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$14.00 ➝ $11.004/29/2026SNDLSNDL Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/20/2026CLLSCellectis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/14/2026CLLSCellectis Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$8.004/7/2026FTLFFitLife Brands Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/2/2026FTLFFitLife Brands Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $18.003/27/2026ALTAltimmune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/18/2026ALTAltimmune Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.003/16/2026ALTAltimmune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $25.003/6/2026ALTAltimmune B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $13.00(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$36K16,098.13N/AN/A$1.46 per share2.04CLLSCellectis$68.07M5.35N/AN/A$0.60 per share6.05FTLFFitLife Brands$90.85M1.02$1.14 per share8.64$4.83 per share2.04SNDLSNDL$937.39M0.40$0.11 per share12.88$3.08 per share0.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.09M-$0.93N/AN/AN/A-214,860.98%-42.57%-35.57%8/11/2026 (Estimated)CLLSCellectis-$67.59M-$0.67N/AN/AN/A-89.51%-80.66%-20.51%7/30/2026 (Estimated)FTLFFitLife Brands$6.33M$0.6016.328.57N/A6.64%18.31%8.21%N/ASNDLSNDL-$11.29M-$0.03N/A36.25N/A-1.19%-1.02%-0.85%7/30/2026 (Estimated)Latest FTLF, SNDL, CLLS, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026FTLFFitLife Brands$0.14$0.17+$0.03$0.17N/A$25.33 million5/13/2026Q1 2026ALTAltimmune-$0.25-$0.18+$0.07-$0.18$0.00 millionN/A5/11/2026Q1 2026CLLSCellectis-$0.2583-$0.18+$0.0783-$0.18$11.04 million$7.55 million3/19/2026Q4 2025CLLSCellectis-$0.10-$0.26-$0.16-$0.26$10.74 million$15.50 million3/12/2026Q4 2025SNDLSNDL$0.01$0.0291+$0.0191$0.03$257.97 million$183.87 million3/5/2026Q4 2025ALTAltimmune-$0.25-$0.2719-$0.0219-$0.27$0.00 million$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.1229.5629.56CLLSCellectis1.131.521.52FTLFFitLife Brands0.781.520.49SNDLSNDL0.124.843.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%CLLSCellectis63.90%FTLFFitLife Brands2.32%SNDLSNDLN/AInsider OwnershipCompanyInsider OwnershipALTAltimmune1.60%CLLSCellectis16.41%FTLFFitLife Brands61.40%SNDLSNDLN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune50194.47 million191.36 millionOptionableCLLSCellectis290100.34 million83.87 millionOptionableFTLFFitLife Brands209.39 million3.63 millionNot OptionableSNDLSNDL2,751257.40 millionN/AOptionableFTLF, SNDL, CLLS, and ALT HeadlinesRecent News About These CompaniesSNDL Announces Update on Arrangement Agreement with 1CM for Acquisition of Ontario Cannabis Stores4 minutes ago | financialpost.comFSNDL Announces Update on Arrangement Agreement with 1CM for Acquisition of Ontario Cannabis Stores22 minutes ago | globenewswire.comMay 2026's Promising Penny Stocks To ConsiderMay 25 at 5:27 PM | finance.yahoo.comTop Canadian Marijuana Stock Choices For Better Investing In 2026May 22, 2026 | marijuanastocks.comMAlliance Global Partners Keeps Their Buy Rating on SNDL (SNDL)May 6, 2026 | theglobeandmail.comATB Cormark Capital Markets Keeps Their Buy Rating on SNDL (SNDL)May 6, 2026 | theglobeandmail.comShould SNDL Stock Be in Your Portfolio Post Q1 Earnings?May 6, 2026 | finance.yahoo.comShould SNDL Stock Be in Your Portfolio Post Q1 Earnings?May 6, 2026 | zacks.comSNDL Inc. (SNDL) Reports its First-quarter 2026 ResultsMay 1, 2026 | finance.yahoo.comSNDL Inc. (SNDL) Reports its First-quarter 2026 ResultsMay 1, 2026 | insidermonkey.comSNDL (NASDAQ:SNDL) Rating Lowered to "Strong Sell" at Zacks ResearchMay 1, 2026 | marketbeat.comSNDL Inc. Q1 2026 Earnings Call SummaryApril 30, 2026 | finance.yahoo.comSNDL Quarterly Revenue Dented By Soft Liquor, Cannabis Market ConditionsApril 30, 2026 | marketwatch.comSNDL sends pot stocks lower as market headwinds drive Q1 revenue missApril 30, 2026 | msn.comForget SNDL: HITI is a Significantly Better Cannabis StockApril 30, 2026 | 247wallst.comForget SNDL: HITI is a Significantly Better Cannabis StockApril 30, 2026 | 247wallst.comSNDL Inc. Disappoints With Declining Q1 2026 RevenueApril 30, 2026 | seekingalpha.comSNDL Inc. Earnings Call: Cost Cuts Amid Cannabis StrainApril 29, 2026 | tipranks.comSNDL Inc. (SNDL) Q1 2026 Earnings Call TranscriptApril 29, 2026 | seekingalpha.comSNDL Q1 Earnings Call HighlightsApril 29, 2026 | marketbeat.comSNDL (SNDL) Q1 2026 Earnings TranscriptApril 29, 2026 | fool.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFTLF, SNDL, CLLS, and ALT Company DescriptionsAltimmune NASDAQ:ALT$2.98 +0.05 (+1.71%) Closing price 04:00 PM EasternExtended Trading$2.99 +0.01 (+0.34%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Cellectis NASDAQ:CLLS$3.63 -0.04 (-1.09%) Closing price 04:00 PM EasternExtended Trading$3.63 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.FitLife Brands NASDAQ:FTLF$9.86 -0.07 (-0.70%) Closing price 04:00 PM EasternExtended Trading$9.90 +0.04 (+0.35%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.SNDL NASDAQ:SNDL$1.45 +0.01 (+0.69%) Closing price 04:00 PM EasternExtended Trading$1.45 0.00 (-0.28%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case TeraWulf Bets on Power Infrastructure to Lead AI Build-Out Zscaler Stock Drops 30%: Why the Dip Is a Buy Opportunity Shake Shack Insiders Buy as SHAK Stock Faces More Pressure Rocket Lab Keeps Making Headlines and Highs—Here's What's Driving the Latest Move Record Revenue, Rising Dividends—So Why Aren't Analysts Saying Buy? Qualcomm's TikTok AI Chip Deal Rewrites the Rules Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
